【摘要】 目的观察阿司匹林联合阿托伐他汀钙治疗急性脑梗死的临床疗效及安全性。方法将184例急性脑梗死患者随机分为对照组92例和试验组92例。对照组予以口服阿司匹林肠溶片100 mg qd;试验组在对照组治疗的基础上,联合口服阿托伐他汀钙20 mg qd。2组患者均治疗14 d。于治疗前和治疗后1,7,14 d,用美国国立卫生研究院卒中量表（NIHSS）进行神经功能缺损评分;于治疗前和治疗后14 d,用酶联免疫吸附实验法检测2组患者的血清C反应蛋白（CRP）、神经元特异性烯醇化酶（NSE）、星形胶质源性蛋白（S100B）水平。比较2组患者的临床疗效及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为96.74%（89/92例）和75.00%（69/92例）,差异均有统计学意义（P<0.05）。治疗后7,14 d,试验组的NIHSS评分分别为（7.34±5.28）,（4.89±3.09）分,对照组的NIHSS评分分别为（10.14±5.33）,（6.91±4.13）分,差异均有统计学意义（P<0.05）。治疗后,试验组和对照组的CRP分别为（4.89±2.13）,（6.34±1.56）mg·L^-1;NSE分别为（8.98±4.91）,（10.46±6.04）μg·L^-1;S100B分别为（0.13±0.13）,（0.19±0.23）μg·L^-1,差异均有统计学意义（P<0.05）。试验组发生的药物不良反应主要有腹胀、嗳气、肢体乏力,对照组发生的药物不良反应主要有恶心、食欲缺乏。试验组和对照组的药物不良反应发生率均为2.17%,差异无统计学意义（P>0.05）。结论阿司匹林联合阿托伐他汀钙治疗急性脑梗死的临床效果显著,且不增加药物不良反应发生率。更多还原

【Abstract】 Objective To observe the clinical efficacy and safety of aspirin combined with atorvastatin calcium in the treatment of acute cerebral infarct.Methods A total of 184 acute cerebral infarct patients were randomly divided into control group（ n = 92） and treatment group（ n = 92）.Control group was treated with aspirin 100 mg,qd.Treatment group was given atorvastatin calcium 20 mg,qd,on the basis of control group.Two groups were treated for 14 d.The neurological function scoring was evaluated by national institute of health stroke scale（ NIHSS） score before treatment and after treatment 1,7,14 d.The serum C-reaction protein（ CRP）,neuron-specific enolase（ NSE）and S100 B levels were tested by enzyme linked immunosorbent assay（ ELISA） before treatment and after treatment 14 d.The clinical efficacyand adverse drug reactions were compared in two groups.Results After treatment,the total effective rates in treatment and control groups were 96.74%（ 89/92） and 75.00%（ 69/92）,with significant difference（ P < 0.05）.After treatment 7,14 d,the NIHSS scores in treatment group were（ 7.34 ± 5.28）,（ 4.89 ± 3.09） point and which in control group were（ 10.14 ± 5.33）,（ 6.91 ± 4.13） point,with statistically significant difference（ P < 0.05）.After treatment,the main indexes in treatment and control groups were compared: CRP were（ 4.89 ± 2.13）,（ 6.34 ± 1.56） mg · L^-1; NSE were（ 8.98 ± 4.91）,（ 10.46 ± 6.04） μg · L^-1; S100 B were（ 0.13 ± 0.13）,（ 0.19 ± 0.23） μg·L^-1,with significant difference（ P < 0.05）.The adverse drug reactions were based on bloating,belching,limb weakness,which in control group were nausea and loss of appetite.There was no significant difference on the incidence of adverse drug reactions between two groups（ 2.17% vs 2.17%,P > 0.05）.Conclusion Aspirin combined with atorvastatin calcium have a definitive clinical efficacy for the treatment of acute cerebral infarct,without increasing the incidence of adverse drug reactions.更多还原